MCID: VSC003
MIFTS: 54

Visceral Leishmaniasis

Categories: Bone diseases, Gastrointestinal diseases, Immune diseases, Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

MalaCards integrated aliases for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 15 17 32
Leishmaniasis, Visceral 44 70
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 54
Kala-Azar 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD9CM 34 085.0
MeSH 44 D007898
NCIt 50 C34771
SNOMED-CT 67 48115004
ICD10 32 B55.0
UMLS 70 C0023290

Summaries for Visceral Leishmaniasis

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to leishmaniasis and neutropenia. An important gene associated with Visceral Leishmaniasis is KAZA1 (Kala-Azar (Visceral Leishmaniasis), Susceptibility To), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs deoxycholic acid and meglumine antimoniate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, spleen and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 73 Visceral leishmaniasis (VL), also known as kala-azar, is the most severe form of leishmaniasis and,... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 818)
# Related Disease Score Top Affiliating Genes
1 leishmaniasis 32.7 TNF TLR4 TLR2 SLC11A1 PGD NOS2
2 neutropenia 31.8 TNF IL2 IL10 ALB
3 hemophagocytic lymphohistiocytosis 31.7 TNF IL18 IL10 IFNG
4 human immunodeficiency virus type 1 31.7 TNF LTA IL2 IL10 IFNG
5 chagas disease 31.6 TNF TLR4 TLR2 NOS2 IL4 IL2
6 acquired immunodeficiency syndrome 31.6 TNF NOS2 IL2 IL10 IFNG ALB
7 disease by infectious agent 31.4 TNF TLR4 TLR2 SLC11A1 LTA IL4
8 cutaneous leishmaniasis 31.4 TNF TLR4 TLR2 SLC11A1 PGD NOS2
9 immune deficiency disease 31.4 TNF TLR2 LTA IL4 IL2 IL18
10 trypanosomiasis 31.3 TNF IL4 IL18 IL10 IFNG ALB
11 bacterial infectious disease 31.3 TNF TLR4 TLR2 SLC11A1 IL18 IL10
12 lymphopenia 31.3 IL4 IL2 IL10 IFNG FOXP3
13 iridocyclitis 31.3 TNF TLR4 IL10
14 acute pancreatitis 31.3 TNF TLR4 IL18 IL10
15 human immunodeficiency virus infectious disease 31.2 TNF IL4 IL2 IL10 IFNG
16 schistosomiasis 31.2 TNF IL4 IL2 IL13 IL10 IFNG
17 mucocutaneous leishmaniasis 31.2 TNF LMLN IL4 IL2 IL13 IL10
18 diarrhea 31.2 TNF TLR4 IL2 IL13 IL10 IFNG
19 portal hypertension 31.1 TNF TLR4 ALB
20 sleeping sickness 31.1 NOS2 LMLN IL10
21 alopecia 31.1 TNF IL4 IL2 IFNG
22 autoimmune hepatitis 31.1 TNF IL4 IL10 FOXP3 ALB
23 toxoplasmosis 31.1 TNF TLR4 TLR2 NOS2 IL4 IL10
24 purpura 31.1 TNF IL4 IL10 IFNG
25 chronic granulomatous disease 31.1 TNF SLC11A1 IL18 IFNG
26 bronchopneumonia 31.1 TNF TLR4 IL10 ALB
27 nephrotic syndrome 31.0 TNF IL4 IL2 IL18 IL13 ALB
28 thrombocytopenia 31.0 TNF TLR4 TLR2 LTA IL4 IL2
29 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 IL10 IFNG FOXP3
30 stomatitis 31.0 TNF IL4 IL2 IL10 IFNG
31 lymphadenitis 31.0 TNF TLR4 SLC11A1 IL18 IL10 IFNG
32 leprosy 3 31.0 TNF TLR4 TLR2 SLC11A1 IL4 IL2
33 lichen planus 31.0 TNF IL4 IL2 IL10 IFNG
34 keratitis, hereditary 30.9 TNF TLR4 TLR2 IL10
35 hypersplenism 30.9 TLR4 LTA IL4 IFNG FOXP3 ALB
36 echinococcosis 30.9 TNF TLR4 TLR2 IL10 IFNG
37 typhoid fever 30.9 TNF TLR4 SLC11A1 LTA IFNG ALB
38 babesiosis 30.9 IL10 HSPA4 ALB
39 liver cirrhosis 30.9 TNF TLR4 TLR2 IL2 IL10 IFNG
40 candidiasis 30.9 TNF TLR4 TLR2 IL4 IL2 IL10
41 hemolytic anemia 30.9 TNF IL4 IL2 IL10 IFNG
42 conjunctivitis 30.9 TNF TLR4 IL4 IL2 IL13 IL10
43 exanthem 30.9 TNF IL2 IL18 IL10 IFNG ALB
44 severe combined immunodeficiency 30.9 IL4 IL2 IL13 IL10 IFNG
45 pulmonary tuberculosis 30.9 TNF TLR2 SLC11A1 IL4 IL2 IL18
46 syphilis 30.8 TNF IFNG FOXP3 ALB
47 brucellosis 30.8 TNF TLR4 SLC11A1 IL4 IL2 IL18
48 scleritis 30.8 TNF IL4 IFNG
49 connective tissue disease 30.8 TNF IL4 IL2 IL10 IFNG ALB
50 miliary tuberculosis 30.8 TNF IFNG ALB

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

GenomeRNAi Phenotypes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.77 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.77 HSPA4
3 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.77 HSPA4
4 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.77 IL13
5 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.77 IL10
6 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.77 IL10
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.77 HSPA4 TLR4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.77 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.77 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.77 IL13
11 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.77 HSPA4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-181 9.77 IL13
13 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.77 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.77 IL13
15 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.77 IL10
16 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.77 IL10
17 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.77 TLR4
18 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.77 IL10
19 Increased shRNA abundance (Z-score > 2) GR00366-A-53 9.77 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.77 IL13
21 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.77 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.77 IL10
23 Increased shRNA abundance (Z-score > 2) GR00366-A-68 9.77 IL10 TLR4
24 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.77 IL10
25 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-89 9.77 HSPA4

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 ALB FOXP3 HSPA4 IFNG IL10 IL13
2 digestive/alimentary MP:0005381 10.35 ALB FOXP3 IFNG IL10 IL13 IL18
3 immune system MP:0005387 10.34 ALB FOXP3 IFNG IL10 IL13 IL18
4 hematopoietic system MP:0005397 10.32 FOXP3 IFNG IL10 IL13 IL18 IL2
5 mortality/aging MP:0010768 10.31 ALB FOXP3 HSPA4 IFNG IL10 IL13
6 cardiovascular system MP:0005385 10.3 ALB FOXP3 IFNG IL10 IL18 IL2
7 endocrine/exocrine gland MP:0005379 10.3 ALB FOXP3 HSPA4 IFNG IL10 IL13
8 integument MP:0010771 10.22 FOXP3 IFNG IL10 IL13 IL18 IL4
9 liver/biliary system MP:0005370 10.2 ALB FOXP3 IFNG IL10 IL2 IL4
10 muscle MP:0005369 10.06 ALB IFNG IL10 IL13 IL18 NOS2
11 neoplasm MP:0002006 10.02 ALB IFNG IL10 IL2 NOS2 SLC11A1
12 reproductive system MP:0005389 9.96 FOXP3 HSPA4 IFNG IL10 IL13 IL2
13 respiratory system MP:0005388 9.9 FOXP3 IFNG IL10 IL13 IL2 IL4
14 no phenotypic analysis MP:0003012 9.87 FOXP3 IFNG IL10 IL13 IL2 IL4
15 skeleton MP:0005390 9.65 IFNG IL10 IL13 IL4 LTA NOS2
16 vision/eye MP:0005391 9.32 FOXP3 IFNG IL10 IL18 IL2 IL4

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
deoxycholic acid Approved Phase 4 83-44-3 222528
2
meglumine antimoniate Experimental, Investigational Phase 4 133-51-7
3 Anti-Bacterial Agents Phase 4
4 Amebicides Phase 4
5 Amphotericin B, deoxycholate drug combination Phase 4
6 Gastrointestinal Agents Phase 4
7
Paromomycin Approved, Investigational Phase 3 1263-89-4, 7542-37-2 165580
8
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
10
Tocopherol Approved, Investigational Phase 3 1406-66-2
11
Pentamidine Approved, Investigational Phase 3 100-33-4 4735
12
Miltefosine Approved, Investigational Phase 3 58066-85-6 3600
13
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
14 Tocotrienol Investigational Phase 3 6829-55-6
15 Antiparasitic Agents Phase 3
16 Antiprotozoal Agents Phase 3
17 Antifungal Agents Phase 3
18 Vitamins Phase 3
19 Tocotrienols Phase 3
20 Tocopherols Phase 3
21 Anti-Infective Agents Phase 2
22 Fat Emulsions, Intravenous Phase 2
23 Soybean oil, phospholipid emulsion Phase 2
24 Pharmaceutical Solutions Phase 2
25 Parenteral Nutrition Solutions Phase 2
26 Soy Bean Phase 2
27 Anthelmintics Phase 2
28 Antimony Sodium Gluconate Phase 2
29 Vaccines Phase 2
30
Acetylcysteine Approved, Investigational 616-91-1 12035
31
Neomycin Approved, Vet_approved 1404-04-2 8378
32
Erythromycin Approved, Investigational, Vet_approved 114-07-8 12560
33
Coal tar Approved 8007-45-2
34
Iron Approved 7439-89-6 23925 29936
35
Albendazole Approved, Vet_approved 54965-21-8 2082
36
Zinc Approved, Investigational 7440-66-6 32051
37
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
38 Antibodies, Anti-Idiotypic
39 Respiratory System Agents
40 Protective Agents
41 Expectorants
42 N-monoacetylcystine
43 Antioxidants
44 Antiviral Agents
45 Antidotes
46 Erythromycin stearate
47 Erythromycin Estolate
48 Erythromycin Ethylsuccinate
49 Tubulin Modulators
50 Nutrients

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Point of Care Diagnosis and Treatment With Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India. Unknown status NCT01566552 Phase 4 AMBISOME
2 A Phase 4 Study to Expand Access Program While Assessing the Safety and Efficacy of Paromomycin IM Injection in an Outpatient Setting for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4 Paromomycin sulfate
3 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4 Mitefosine
4 Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh Completed NCT03311607 Phase 4 AmBisome
5 Efficacy and Safety of Amphotericin B Deoxycholate Compared to Meglumine Antimoniate for Treatment of Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4 Meglumine antimoniate;Amphotericin B-deoxycholate
6 Multicentric Efficacy and Safety Study of Antileishmanial Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4 Antimoniate of N-methylglucamine;amphotericin B deoxycholate;Liposomal amphotericin B;Liposomal amphotericin B;Antimoniate of N-methylglucamine
7 A Phase III, Open Label, Randomised, Study of Three Short Course Combination Regimens (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome® Alone for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01122771 Phase 3 Liposomal amphotericin B;liposomal amphotericin B + miltefosine;liposomal amphotericin B + paromomycin;Miltefosine + Paromomycin
8 A Prospective, Multicentric, Randomized, Two Arm, Open Label Phase III Study To Assess Efficacy And Safety Of Infusion Of Amphomul® (Amphotericin B Emulsion) As Compared To Liposomal Amphotericin In Patients Of Visceral Leishmaniasis (Kala Azar) Completed NCT00876824 Phase 3 Amphotericin B Lipid emulsion;Liposomal Amphotericin B
9 A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL Completed NCT02193022 Phase 3 Miltefosine
10 A Randomised, Open-label, Parallel-group, Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens (Co-administration), of AmBisome, Paromomycin and Miltefosine in Visceral Leishmaniasis (VL) Completed NCT00523965 Phase 3 amphotericin B deoxycholate;Liposomal Amphotericin B with Miltefosine;Liposomal Amphotericin B and Paromomycin Sulfate;miltefosine + Paromomycin sulfate
11 A Multicentre Comparative Trial of Efficacy and Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) Versus Combination of SSG and PM as the First Line Treatment for Visceral Leishmaniasis in Ethiopia, Kenya and Sudan Completed NCT00255567 Phase 3 Sodium Stibogluconate;Paromomycin sulphate;SSG and Paromomycin sulphate
12 A Phase 3 Multicenter, Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Injectable Paromomycin in Patients With Visceral Leishmaniasis Completed NCT00216346 Phase 3 Paromomycin sulfate;Amphotericin B
13 An Open Lable Randomised Two -Arm Study to Assess the Safety and Efficacy of Paromomycin Administered Intramuscularly at Two Different Dosing Regimens (14 Days Versus 21 Days) for the Treatment of Indian Visceral Leishmaniasis (VL) Completed NCT00629031 Phase 3 Paromomycin;Paromomycin
14 A Phase III Randomized, Controlled, Clinical Trial to Assess the Safety and Efficacy of Single Infusion of Liposomal Amphotericin B in Patients With Visceral Leishmaniasis Completed NCT00628719 Phase 3 Liposomal Amphotericin B;amphotericin B deoxycholate
15 A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine. Completed NCT02011958 Phase 3 Liposomal Amphotericin B;Miltefosine
16 Randomized, Open-label, Parallel-group, Safety & Efficacy Study to Evaluate Different Combination Treatment Regimens, of Either AmBisome and Paromomycin, AmBisome and Miltefosine, or Paromomycin and Miltefosine Compared With Amphotericin B Deoxycholate (the Standard) Therapy for the Treatment of Acute, Symptomatic Visceral Leishmaniasis (VL). Completed NCT00696969 Phase 3 Amphotericin B Deoxycholate;Ambisome + Miltefosine;Ambisome and Paromomycin;Miltefosine and Paromomycin
17 Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study Completed NCT01360762 Phase 3 Pentamidine
18 Replacement of Insecticides to Control Visceral Leishmaniasis Completed NCT01644682 Phase 3
19 An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Active, not recruiting NCT03129646 Phase 3 Miltefosine;Paromomycin;Sodium stibogluconate
20 The Efficacy and Safety of a Short Course of Miltefosine and Liposomal Amphotericin B for Visceral Leishmaniasis in India Completed NCT00371995 Phase 2 Liposomal amphotericin B and Miltefosine
21 A Prospective, Single Center, Open-Label, Dose-Escalation Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Treatment Naïve Or Resistant Cases Of Visceral Leishmaniasis (Kala-Azar). Completed NCT00497601 Phase 2 Amphotericin B fat emulsion in visceral leishmaniasis;Amphotericin B fat emulsion;Amphotericin B in fat emulsion
22 A Phase II, Multi-centre, Open-label, Randomised Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral Sitamaquine Compared With Amphotericin B in the Treatment of Visceral Leishmaniasis Caused by L. Donovani in Endemic Areas. Completed NCT00381394 Phase 2 sitamaquine
23 Combination Chemotherapy for the Treatment of Indian Visceral Leishmaniasis: Miltefosine Plus Liposomal Amphotericin B - Dose and Duration Ranging Study Completed NCT00370825 Phase 2 Combination therapy with AmBisome and miltefosine
24 A Phase II Randomized, Parallel Arm, Open-labeled Clinical Trial to Assess the Safety and Efficacy of the Combination of Sodium Stibogluconate Plus Single Dose AmBisome®, Miltefosine Plus Single Dose AmBisome® and Miltefosine Alone for the Treatment of Primary Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2 Liposomal amphotericin B (AmBisome®) and sodium stibogluconate;Liposomal amphotericin B + miltefosine;Miltefosine
25 An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa Completed NCT02431143 Phase 2 Miltefosine
26 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2 Miltefosine;Miltefosine
27 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2 Sodium Stibogluconate (SSG)
28 Department of Defense Protocol for the Use of Sodium Stibogluconate (Pentostam) as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2 Sodium Stibogluconate (SSG)
29 A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Completed NCT02687971 Phase 2 Miltefosine
30 An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan Recruiting NCT03399955 Phase 2 Paromomycin;Ambisome;Miltefosine
31 A Phase IIb Study to Assess the Safety, Efficacy and Immunogenicity of the Leishmania Vaccine ChAd63-KH in Post-kala Azar Dermal Leishmaniasis Recruiting NCT03969134 Phase 2
32 A Phase II Study to Assess the Safety and Efficacy of the Leishmania Vaccine ChAd63-KH for the Prevention of Post-kala Azar Dermal Leishmaniasis Not yet recruiting NCT04107961 Phase 2
33 Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan Terminated NCT01980199 Phase 2 Fexinidazole
34 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2 Miltefosine: initially 2.5 mg/kg/day for 28 days
35 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis Terminated NCT00832208 Phase 2 Liposomal amphotericin B (Ambisome);Liposomal amphotericin B (Ambisome)
36 A Phase I/II Clinical Trial To Assess the Safety and Biologic Activity of the Anti-IL-10 Monoclonal Antibody, SCH708980, in Combination With AmBisome(Registered Trademark), Versus That of Placebo in Combination With Ambisome(Registered Trademark), in Subjects With Visceral Leishmaniasis (VL) Withdrawn NCT01437020 Phase 1, Phase 2 SCH708980 Anti-IL-10 monoclonal;AmBisome
37 A Phase 1, Open-Label, Dose Escalating Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-111F + MPL-SE Vaccine (Recombinant Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE) in Healthy Adults In India Completed NCT00486382 Phase 1
38 Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine in Combination With SSG in the Treatment of Patients With PKDL Completed NCT00982774 Phase 1
39 Multi-Center, Open-Label, Randomized, Two Treatment, Parallel, Single Period, Multiple-Dose, Steady State, Global Bioequivalence Study of Amphotericin B Liposome for Injection 50mg /Vial in Patients With Visceral Leishmaniasis Completed NCT03636659 Phase 1 Amphotericin B Liposome;AmBisome (Amphotericin B) Liposome
40 A Phase I, Double-blind, Randomised, Single Centre, Parallel Group, Single-dose, Dose-escalation, Placebo Controlled Study of the Safety, Tolerability and Pharmacokinetics of DNDI-0690 After Oral Dosing in Healthy Subjects Completed NCT03929016 Phase 1 DNDI-0690;Placebo of DNDI-0690
41 A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects Completed NCT02071758 Phase 1
42 Evaluation of Antibody Detection Tests for Visceral Leishmaniasis Diagnosis in Eastern Africa Unknown status NCT03646981
43 Study for Evaluation of the Immune Response of Visceral Leishmaniasis Patients Treated With Antimonial Pentavalent Associated to N-Acetylcysteine Unknown status NCT01138956 N-acetylcysteine;Pentavalent antimonial
44 ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum Unknown status NCT03303898
45 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457 Paromomycin sulfate
46 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473 Randomized trial for treatment of kala azar in Bangladesh
47 Randomised Double Blind Dose Ranging Study of Amphotericin B in Visceral Leishmaniasis Completed NCT00310505 Amphotericin B deoxycholate given as daily administration
48 Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar Completed NCT00318721
49 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
50 A Randomized, Double Blind, Community Trial to Assess the Efficacy of a Combination of Anti-helminth, and Vitamin A, Zinc and Iron Supplementation in Preventing Visceral Leishmaniasis (VL) Disease Among Asymptomatic Individuals With VL Completed NCT01069198 Albendazole, Iron, Zinc and Vitamin A

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Meglumine
Pentamidine
Pentamidine Isethionate

Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

40
Bone Marrow, Spleen, T Cells, Liver, Lymph Node, Myeloid, Monocytes

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 8680)
# Title Authors PMID Year
1
Plasma lipoproteins in visceral leishmaniasis and their effect on Leishmania-infected macrophages. 61 54
20398226 2010
2
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis. 61 54
20404924 2010
3
Immunologic indicators of clinical progression during canine Leishmania infantum infection. 54 61
20032217 2010
4
In situ immune responses to interstitial pneumonitis in human visceral leishmaniasis. 61 54
19149777 2009
5
Increased levels of IL-10, IL-12, and IFN- in patients with visceral leishmaniasis. 61 54
19578629 2009
6
Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis. 61 54
18948098 2009
7
IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. 54 61
17911647 2007
8
Interleukin-10 and the pathogenesis of human visceral leishmaniasis. 61 54
17689290 2007
9
Immunopathology of leishmaniasis: an update. 54 61
17880757 2007
10
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. 54 61
17389235 2007
11
Cystatin C as a marker of immune complex-associated renal impairment in a Sudanese population with visceral leishmaniasis. 61 54
17123978 2006
12
Mixed inflammatory/regulatory cytokine profile marked by simultaneous raise of interferon-gamma and interleukin-10 and low frequency of tumour necrosis factor-alpha(+) monocytes are hallmarks of active human visceral Leishmaniasis due to Leishmania chagasi infection. 61 54
16968407 2006
13
Immunology of canine leishmaniasis. 54 61
16842269 2006
14
Balance of IL-10 and interferon-gamma plasma levels in human visceral leishmaniasis: implications in the pathogenesis. 61 54
16364177 2005
15
Leishmania donovani: effect of therapy on expression of CD2 antigen and secretion of macrophage migration inhibition factor by T-cells in patients with visceral leishmaniasis. 54 61
16023642 2005
16
Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs. 54 61
15619517 2005
17
Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis. 61 54
15569785 2004
18
Adjunct effect of immunostimulating hexapeptide analogous to human beta-casein fragment (54-59) to sodium stibogluconate against experimental visceral leishmaniasis. 61 54
15518175 2004
19
Immunity and immunosuppression in experimental visceral leishmaniasis. 61 54
15064826 2004
20
Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. 54 61
12618857 2003
21
Cellular profile of cytokine production in a patient with visceral leishmaniasis: gammadelta+ T cells express both type 1 cytokines and interleukin-10. 54 61
12641659 2003
22
Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. 54 61
12379707 2002
23
Association analysis of HLA-class II and class III gene polymorphisms in the susceptibility to mediterranean visceral leishmaniasis. 61 54
11334675 2001
24
Reactive oxygen intermediates, nitrite and IFN-gamma in Indian visceral leishmaniasis. 61 54
11422203 2001
25
Tissue cytokine responses in canine visceral leishmaniasis. 54 61
11294678 2001
26
Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. 54 61
11280075 2001
27
IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. 61 54
10930301 2000
28
HIV-1 alters T helper cytokines, interleukin-12 and interleukin-18 responses to the protozoan parasite Leishmania donovani. 54 61
10853973 2000
29
Role of CD8+ T cells in endogenous interleukin-10 secretion associated with visceral leishmaniasis. 61 54
10733741 2000
30
High levels of C-reactive protein in the peripheral blood during visceral leishmaniasis predict subsequent development of post kala-azar dermal leishmaniasis. 61 54
10708005 2000
31
A novel Leishmania infantum recombinant antigen which elicits interleukin 10 production by peripheral blood mononuclear cells of patients with visceral leishmaniasis. 61 54
10639426 2000
32
Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. 54 61
10361241 1999
33
T cell response of asymptomatic Leishmania chagasi infected subjects to recombinant leishmania antigens. 54 61
10348984 1999
34
Increased levels of soluble interleukin-4 receptor in the sera of patients with visceral leishmaniasis. 61 54
9952391 1999
35
T-cell response in human leishmaniasis. 61 54
10065635 1999
36
Splenic cytokine responses in Indian kala-azar before and after treatment. 54 61
9498473 1998
37
Human_leishmaniasis/cytokines.bahia.br. 61 54
9686193 1998
38
High levels of plasma IL-10 and expression of IL-10 by keratinocytes during visceral leishmaniasis predict subsequent development of post-kala-azar dermal leishmaniasis. 61 54
9472662 1998
39
Presence of circulating levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha in patients with visceral leishmaniasis. 54 61
9713135 1998
40
Cytokine profile and pathology in human leishmaniasis. 61 54
9686192 1998
41
Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. 61 54
9333181 1997
42
Protective effect of neoglycoprotein-conjugated muramyl dipeptide against Leishmania donovani infection: the role of cytokines. 54 61
9164956 1997
43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. 61 54
9180602 1997
44
Behavior of visceral Leishmania donovani in an experimentally induced T helper cell 2 (Th2)-associated response model. 61 54
9120392 1997
45
Current and future clinical applications of interferon-gamma in host antimicrobial defense. 61 54
8923089 1996
46
Antimony/interferon-gamma combination in the treatment of visceral leishmaniasis in AIDS. 54 61
8874638 1996
47
Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. 54 61
8648233 1996
48
Effect of treatment with interferon-gamma alone in visceral leishmaniasis. 54 61
7594733 1995
49
In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. 61 54
8580385 1995
50
Treatment of visceral leishmaniasis in a patient with AIDS with antimony and gamma-interferon: remission and prevention of relapse by maintenance therapy with weekly pentamidine. 61 54
7566284 1995

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.09 TNF TLR4 TLR2 SLC11A1 NOS2 LTA
2
Show member pathways
13.75 TNF TLR4 NOS2 LTA IL4 IL2
3
Show member pathways
13.58 TNF LTA IL4 IL2 IL18 IL13
4
Show member pathways
13.48 TNF TLR4 TLR2 LTA IL4 IL2
5
Show member pathways
13.44 TNF NOS2 LTA IL4 IL2 IL18
6
Show member pathways
13.35 TNF LTA IL4 IL2 IL18 IL13
7
Show member pathways
13.28 TNF TLR4 TLR2 NOS2 IL2 IL18
8
Show member pathways
12.91 TNF LTA IL4 IL2 IL13 IL10
9
Show member pathways
12.9 TNF TLR4 TLR2 IL2 IL18 IFNG
10 12.86 NOS2 IL4 IL2 IL13 IFNG
11
Show member pathways
12.76 TNF TLR4 TLR2 NOS2 IL18
12
Show member pathways
12.74 TNF TLR4 TLR2 LTA IL2
13
Show member pathways
12.72 TNF IL4 IL2 IL18 IL10 IFNG
14
Show member pathways
12.7 TNF TLR4 TLR2 IL4 IL2 IL10
15
Show member pathways
12.68 TNF NOS2 IL2 IL18 IL10 IFNG
16 12.66 TNF TLR2 IL4 IL2 IL10 IFNG
17
Show member pathways
12.5 IL4 IL2 IL13 IL10 IFNG
18
Show member pathways
12.49 TNF TLR4 TLR2 IL4 IL2 IL18
19
Show member pathways
12.43 TNF TLR2 IL4 IL13 IFNG
20
Show member pathways
12.43 TNF LTA IL2 IL18 IL10
21
Show member pathways
12.42 TNF IL4 IL2 IFNG ALB
22
Show member pathways
12.36 TNF LTA IL4 IL2 IL18 IL13
23
Show member pathways
12.34 TNF TLR4 NOS2 IFNG
24
Show member pathways
12.34 TNF TLR4 TLR2 NOS2 IL4 IL10
25
Show member pathways
12.29 TNF TLR4 TLR2 NOS2 IL4 IFNG
26 12.29 TNF TLR4 TLR2 NOS2 IL18 IL10
27 12.28 TNF TLR4 TLR2 NOS2 IFNG
28 12.18 TNF TLR4 IL2 IL18 IL10
29 12.13 TNF TLR4 NOS2 IL4 IL2 IFNG
30
Show member pathways
12.11 TLR4 TLR2 IL2 IL13
31 12.1 TNF IL4 IL2 IL10 IFNG
32 12.1 TNF NOS2 IL4 IL18 IL13 IL10
33
Show member pathways
12.09 NOS2 IL4 IL2 IL18 IFNG
34 12.04 TNF TLR4 TLR2 NOS2 IL10 IFNG
35 11.99 TNF TLR4 TLR2 IL18 IFNG
36
Show member pathways
11.96 TLR4 TLR2 IL4 IFNG
37 11.91 IL4 IL2 IL13 IFNG
38
Show member pathways
11.88 TNF IL4 IL2 IFNG FOXP3
39 11.86 TNF TLR4 NOS2 IL10
40 11.85 TNF IL2 IL10 IFNG
41
Show member pathways
11.8 LTA IL4 IL2 FOXP3
42
Show member pathways
11.77 TNF NOS2 IL2 IFNG
43 11.71 TNF IL4 IL13
44 11.71 LTA IL4 IL10
45 11.71 TNF TLR4 TLR2 IL18
46
Show member pathways
11.69 TNF IL2 IFNG
47 11.67 TNF IL4 IL18 IL13 IL10
48
Show member pathways
11.66 TNF LTA IFNG HSPA4
49 11.66 TNF LTA IL4 IL2 IL18 IL13
50 11.63 TNF TLR4 LTA

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 TNF LTA IL4 IL2 IL18 IL13

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TNF TLR4 TLR2 SLC11A1 IL4 IL2
2 defense response to bacterium GO:0042742 10.06 TNF TLR4 SLC11A1 NOS2 IL10
3 inflammatory response GO:0006954 10.05 TNF TLR4 TLR2 SLC11A1 NOS2 IL18
4 cytokine-mediated signaling pathway GO:0019221 10.02 TNF NOS2 IL4 IL2 IL18 IL13
5 positive regulation of gene expression GO:0010628 10.02 TNF TLR4 TLR2 SLC11A1 IL4 IL18
6 cellular response to lipopolysaccharide GO:0071222 10.01 TNF TLR4 NOS2 IL10
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF TLR4 TLR2 IL18
8 negative regulation of inflammatory response GO:0050728 9.97 IL4 IL2 IL13 IL10 FOXP3
9 positive regulation of interleukin-6 production GO:0032755 9.94 TNF TLR4 TLR2 IFNG
10 defense response to Gram-negative bacterium GO:0050829 9.92 TLR4 SLC11A1 NOS2
11 negative regulation of tumor necrosis factor production GO:0032720 9.92 TLR4 IL4 IL10 FOXP3
12 negative regulation of interleukin-6 production GO:0032715 9.92 TNF TLR4 IL10 FOXP3
13 regulation of insulin secretion GO:0050796 9.91 TNF NOS2 IFNG
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.9 TNF IL18 IL13
15 positive regulation of interleukin-8 production GO:0032757 9.9 TNF TLR4 TLR2
16 humoral immune response GO:0006959 9.9 TNF LTA IFNG
17 positive regulation of interleukin-1 beta production GO:0032731 9.9 TNF TLR4 IFNG
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF TLR4 TLR2 IL18
19 positive regulation of cytokine production GO:0001819 9.89 TNF SLC11A1 IL10 IFNG
20 positive regulation of inflammatory response GO:0050729 9.88 TNF TLR4 TLR2 IL2 IL18 IFNG
21 positive regulation of phagocytosis GO:0050766 9.87 TNF SLC11A1 IFNG
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.87 TNF TLR4 IFNG
23 negative regulation of interferon-gamma production GO:0032689 9.87 TLR4 IL10 FOXP3
24 positive regulation of interleukin-12 production GO:0032735 9.87 TLR4 TLR2 IFNG
25 negative regulation of endothelial cell apoptotic process GO:2000352 9.86 IL4 IL13 IL10
26 negative regulation of cytokine production GO:0001818 9.86 SLC11A1 IL10 FOXP3
27 positive regulation of B cell proliferation GO:0030890 9.86 TLR4 IL4 IL2 IL13
28 positive regulation of chemokine production GO:0032722 9.85 TNF TLR4 TLR2 IFNG
29 positive regulation of interleukin-10 production GO:0032733 9.84 TLR4 TLR2 IL4 IL13
30 lipopolysaccharide-mediated signaling pathway GO:0031663 9.83 TNF TLR4 TLR2 IL18
31 negative regulation of interleukin-17 production GO:0032700 9.82 TLR4 IFNG FOXP3
32 positive regulation of macrophage activation GO:0043032 9.81 TLR4 IL13 IL10
33 positive regulation of immunoglobulin production GO:0002639 9.8 IL2 IL13 IL10
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.79 TLR4 TLR2 IFNG
35 regulation of regulatory T cell differentiation GO:0045589 9.78 IL2 IFNG FOXP3
36 macrophage activation GO:0042116 9.76 TLR4 SLC11A1 IL4 IL13
37 positive regulation of neuroinflammatory response GO:0150078 9.75 TNF IL18
38 I-kappaB phosphorylation GO:0007252 9.75 TLR4 TLR2
39 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
40 response to molecule of bacterial origin GO:0002237 9.74 TLR2 IL10
41 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.74 TNF TLR4
42 cellular response to lipoteichoic acid GO:0071223 9.74 TLR4 TLR2
43 T-helper 1 type immune response GO:0042088 9.74 TLR4 IL18
44 negative regulation of T-helper 17 cell differentiation GO:2000320 9.74 IL4 IL2 FOXP3
45 positive regulation of isotype switching to IgG isotypes GO:0048304 9.73 IL4 IL2
46 positive regulation of mast cell degranulation GO:0043306 9.73 IL4 IL13
47 regulation of immunoglobulin production GO:0002637 9.73 TNF FOXP3
48 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
49 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 TLR4 IL4 IL10 IFNG
50 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.73 TNF IL4 IL2 IL18 IL13 IFNG

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF LTA IL4 IL2 IL18 IL13
2 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....